Protein-Based COVID-19 Vaccine Has Similar Efficacy To mRNA, Vector-Based Vaccines, Study Finds

Infectious Disease Advisor (4/18) reports, “NVX-CoV2373, a protein-based COVID-19 vaccine, has high initial efficacy against pre-Delta and Delta strains of the virus and a durability profile similar to that of mRNA and vector-based vaccines, according to findings published in Clinical Infectious Diseases.” However, the study found “protection conferred by 2 doses of NVX-CoV2373 against Delta strains significantly waned over time (P =.007). The vaccine efficacy of NVX-CoV2373 against Delta strains was 88% at day 40, 82% at day 120, and 77% at day 180.”